# A Study of Pyrotinib Plus Capecitabine in Patients With Brain Metastases From HER2-positive Metastatic Breast Cancer

> **NCT03691051** · PHASE2 · UNKNOWN · sponsor: **Henan Cancer Hospital** · enrollment: 78 (actual)

## Conditions studied

- HER2 Positive Metastatic Breast Cancer

## Interventions

- **DRUG:** Pyrotinib plus Capecitabine

## Key facts

- **NCT ID:** NCT03691051
- **Lead sponsor:** Henan Cancer Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-11-20
- **Primary completion:** 2021-04-16
- **Final completion:** 2024-12-30
- **Target enrollment:** 78 (ACTUAL)
- **Last updated:** 2023-09-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03691051

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03691051, "A Study of Pyrotinib Plus Capecitabine in Patients With Brain Metastases From HER2-positive Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03691051. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*